

## AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### In the Claims

Claims 1-5 (cancelled)

~~Claim 6 (currently amended): An isolated compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus (RSV), wherein more than one of cysteines 173, 176, 182 and 186 is absent or blocked, wherein said compound is not glycosylated, and wherein said compound has the ability to inhibit infectivity of RSV.~~

Claims 7-8 (cancelled)

~~Claim 9 (previously amended): A compound according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid.~~

Claim 10 (cancelled)

~~Claim 11 (previously amended): A compound according to claim 6, wherein the compound is labelled with a detectable marker.~~

~~Claim 12 (previously amended): A compound according to claim 11, wherein the detectable marker is a radioactive label.~~

~~Claim 13 (previously amended): A compound according to claim 11, wherein the detectable marker is a fluorescent, chemiluminescent or enzymic marker.~~

Claims 14-15 (cancelled)

Claim 16 (withdrawn): An antibody directed against a compound selected from the group consisting of the compounds of Claims 1 to 10.

Claim 17 (withdrawn): An antibody according to Claim 16 which is a protective antibody.

Claim 18 (withdrawn): A composition comprising antibody selected from the group of the antibodies of Claim 16 and Claim 17.

Claims 19-20 (cancelled)

Claim 21 (withdrawn): A composition according to any one of Claim 16 in which the virus is human RSV.

Claim 22 (cancelled)

Claim 23 (withdrawn): A method of diagnosis of *Pneumovirus* infection, comprising exposing a biological fluid or sample from a mammal suspected of being infected with said virus to a compound selected from the group consisting of the compounds of Claims 1 to 10, and measuring the interaction between the compound and said fluid or sample.

Claim 24 (cancelled)

Claim 25 (withdrawn): A method of identification of a cell surface receptor for respiratory syncytial virus G protein, comprising the step of detection of binding of a compound selected from the group consisting of the compounds of Claims 11 to 13 to a cell surface protein.

Claim 26 (cancelled)

Claim 27 (withdrawn): A method according to Claim 25, in which the cell is susceptible to infection by respiratory syncytial virus.

Claim 28 (withdrawn): A method according to Claim 25, in which the cell is a HEp-2 cell.

Claim 29 (withdrawn): A method according to Claim 25, in which the method comprises the step of photoaffinity labelling of the receptor with a benzoylbenzyl derivative of the compound.

Claim 30 (withdrawn): A method according to Claim 25, in which the method comprises the step of labelling of the receptor with a fluorescent derivative of the compound.

Claim 31 (withdrawn): A method according to Claim 25, in which the method comprises the steps of binding a biotinylated derivative of the compound to a receptor, and binding of avidin to the derivative.

Claim 32 (withdrawn): A method according to Claim 25, in which the method comprises the step of using an antibody according to Claim 16 to detect the binding of the compound.

Claim 33 (withdrawn): A method according to Claim 25, in which the compound is multiply derivatised, thereby to achieve combined cross-linking, detection and identification of a receptor.

Claim 34 (previously amended): A compound according to claim 6, wherein the contiguous sequence represents residues 149 to 177 of the G protein of RSV.

Claim 35 (previously amended): A diagnostic composition comprising a compound according to claim 6.

Claim 36 (cancelled)

Claim 37 (previously added): A diagnostic composition according to claim 35, wherein one or more amino acids is replaced by its corresponding D-amino acid.

Claim 38 (cancelled)

Claim 39 (previously amended): A composition comprising a compound according to claim 6, together with a pharmaceutically acceptable carrier. *the polypeptide*

Claim 40 (cancelled)

Claim 41 (previously amended): A composition comprising a compound according to claim 6, wherein one or more amino acids is replaced by its corresponding D-amino acid. *the polypeptide*

Claim 42 (cancelled)

Claim 43 (previously added): A compound according to claim 6, comprising the amino acid sequence KQRQNKPSPKPNNDHFEVFNFVPCSCIG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl. *the polypeptide*

Claim 44 (previously added): A compound according to claim 6, consisting of acetyl-KQRQNKPSPKPNNDHFEVFNFVPCSCIGAmide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl. *the polypeptide*

Claim 45 (previously added): A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with the compound of claim 6. *human* *polypeptide*

Claim 46 (previously added): A method according to claim 45, wherein the contiguous sequence of amino acids represents residues 149 to 177 of the G protein of RSV. *human* *13* *14*

~~sub~~ 15 Claim 47 (previously added): A method according to claim 45, wherein the ~~compound~~ 13 <sup>polypeptide</sup> comprises the amino acid sequence KQRQNKPSKPNNDFHFEVFNFVPCSICG (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

~~sub~~ 16 13 Claim 48 (previously added): A method according to claim 45, wherein the ~~compound~~ is acetyl-KQRQNKPSKPNNDFHFEVFNFVPCSICGAmide (SEQ ID NO:39), wherein the cysteine residues are derivatized with acetamidomethyl.

Claim 49 (previously added): A method of inhibiting the cytopathic effect of RSV, comprising contacting an RSV susceptible cell with a compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 of the G protein of respiratory syncytial virus (RSV).

~~G~~ 17 <sup>An isolated polypeptide</sup> ~~condid.~~ Claim 50 (currently amended): A compound comprising a contiguous sequence of amino acids within the sequence representing residues 149-197 <sup>177</sup> of the G protein of <sup>human</sup> respiratory syncytial virus (RSV), wherein ~~neither~~ <sup>none</sup> of cysteines 173, <sup>or</sup> 176, 182 and 186 is functional to form a disulfide bridge, wherein said compound is not glycosylated, and wherein said compound has the ability to inhibit infectivity of RSV.